Lysine Biotech Logo

LYSINE BIOTECH PRIVATE LIMITED
 Product development and Manufacture of drugs, biomarkers and vaccines from Protein and DNA
 CIN:U74999TN2018PTC122879
 

Research and Development

We are currently involved in new approaches to providing affordable, safe, and effective biosimilar is a copy of a biological medical drug that is similar, but not identical, to the original biologic medical drug, The path to their approval is shorter as clinical trials and spend on research & development is much less than on the original biologic medical drug, thus fostering cheaper cost.

1.Development of automated large-scale manufacturing systems for CAR-T cells

To make a new approach to provide affordable, safe, and effective mAb sequences used for CAR T (Autologous & Allogeneic) Target-- scFv are originated from Pangene Biotech Ltd

2.Kembrolizumab- Pembrolizumab Biosimilars
Target beneficiary and impact:
Drawbacks in the existing state-of-the-art " Merck & Co".

Pembrolizumab: It consists of 2 heavy and 2 light chains. Each light chain consists of 218 amino acids. Each heavy chain consists of 447 amino acids and Protein Chemical Formula C6504 H10004 N1716 O2036 S46

How these drawbacks have been overcome by "LYSINE BIOTECH"

Kembrolizumab: Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 158 amino acids. Each heavy chain consists of 309 amino acids and Protein Chemical Formula C4434 H6948 N1210O1412 S34

This research is of utmost importance for the treatment of a wide variety of cancers.

3.Kilirag-1 drug for treating Type 2 diabetes-in obese a bit better relative to "Novo Nordisk"

This project aims to the development of human (homo sapiens) specific glucagon-like peptide 1 (GLP-1) nature-derived conventional solid-phase chemical synthesis. The protein sequence for eukaryote glucagon-like peptide 1 (GLP-1) human (homo sapiens) would be produced conventionally solid-phase chemical synthesis, Lyophilized powder, and production of Kilirag-1 drugs. The eukaryote glucagon-like peptide 1 (GLP-1) would be therapeutics for type 2 diabetes in obese.

Approach:

Aim: Targeting glucagon-like peptide 1 (GLP-1) to set up a Kilirag-1 therapeutics for type 2 diabetes in obese a bit better relative to "Novo Nordisk".

Methods:

i) Retrieving all eukaryote glucagon-like peptide 1 (GLP-1) protein IDs from NCBI. ii) Checking the mRNA and protein expression of all GLP1 proteins across various types of GLP1 sequences with different lengths at the eukaryote portal database. iii) Calculating and visualization the mRNA and protein expression correlation of all GLP1 proteins across various types of different glucagon-like peptide 1 (peptide /protein) sequences with different lengths using software analysis tools. iv) Visualization of the mRNA and protein expression correlation of top GLP1 protein candidates across various types of glucagon-like peptide 1 (peptide /protein) sequences with different lengths using biocomputational software analysis tools. v) The peptide purified with HPLC using water and acetonitrile as flow buffers and LC-MS will reveal amino acids peptide sequence and protein structure and any chemical modification with molecular weights will be conformed. vi) The collected fractions are lyophilized to get the pure Kilirag-1 in a powder or vial drug purification and production of Kilirag-1 drugs. vii) Development of novel Kilirag-1 drug activity by cell line. viii) Application of novel Kilirag-1 drugs therapeutics for type 2 diabetes in obese in specific animal models models. ix) Proof of Kilirag-1 concept in health-specific animal models to be ready for clinical trials/patent application.

Deliverable:

Since existing peptides have limited synthetic routes with vast limitations, it has now become necessary to explore novel approaches, for the synthesis of existing/new peptides that are beyond traditional solid-phase peptide synthesis is a very economical method for the synthesis of amino acid peptides that result in high purities. Production costs are less expensive due to the convergent approaches.

Target beneficiary and impact:
Drawbacks in the existing state of art "Novo Nordisk".

Liraglutide and semaglutide are a fragment of the naturally occurring human glucagon-like peptide-1 sequence position 7-37 (GLP-1) and with the addition of a fatty acid chain (palmitoyl group on Lys). liraglutide and semaglutide higher-cost drug protocol higher dosage from protein chemical formula C172H265N43O51 and C187H291N45O59 Protein average weight 3751.2 Da and 4113.64 Da, on the other hand, long peptide-based drugs generally suffer from short half-lives due to proteolytic degradation and fast renal clearance, which require high cost and higher doses/frequency of injections liraglutide 0.6 mg, for once- 1 day and semaglutide 0.25 mg, for once-7 days.

Side effects related to thyroid cancer and other diseases.

How these drawbacks have been overcome by "LYSINE BIOTECH"

Kilirag-1 IND/Biobetter drug is a fragment of the naturally occurring human glucagon-like peptide-1 sequence position 7-37 (GLP-1). low-cost effective drug Kilirag-1 lower dosage from protein molecular formula C60H89N23O19 and Protein average weight 1435 Da, on the other hand, low cost and lower of doses/frequency of injections Kilirag-1 0.2 mg, for once-8 days

Mechanism of action (MOA) is different from the existing Liraglutide and semaglutide "Novo Nordisk".

No side effects related to any other diseases.

This research is of utmost importance for treating type 2 diabetes in obese and other incretin related diseases.

The new approaches in the Pan corona vaccine market is a USD 350bn to USD 410bn in value annually market, which is derived from Proteins, which is a synthetic chemical that can be made from a natural product (i.e. naturally derived) on the Virus (PAN coronavirus) proteins. People worldwide are becoming more Synthetic chemical protein subunit vaccines and shifting to the virus (PAN coronavirus) protein-based products. This shift would help increase the demand for the company’s Synthetic chemical-based protein subunit vaccine alternatives. LBPL plans to achieve at least 10% global market share in the next 3-5 years.
4.Human coronavirus hCoV-19/India 1st, 2nd & 3rd waves COVID-19
Available.

We put emphasis that this computationally developed predicts protein sequence while the invention of a new novel study suggests that thymine content (uracil) in protein-coding RNA sequences is randomly distributed. Thymine content distribution is used here to examine how-19/India genome (hCoV-19/ India types 1-3). Frames are arriving as expected, single-stranded RNA first three frames, in the hot-19/India genomes types 1-3. SPIKE & Nucleocapsid -Frame-1 and RdRp-Frame-3 prefer to have a definite amount of protein-coding hCoV-19/India -3rd COVID-19 wave 2021). SPIKE & Nucleocapsid -Frame-2 and RdRp-Frame-1 were observed in the protein-coding hCoV-19/India -2nd COVID-19 wave 2021 and SPIKE & Nucleocapsid -Frame-3 and RdRp-Frame-2 were also involved protein-coding hCoV-19/India-1st COVID-19 wave 2020. In addition, the results reveal that there was a difference between (hCoV-19/India-1st, 2nd & 3rd COVID-19 types 1-3.

HCV-19/India-1st, 2nd & 3rd waves COVID-19 types 1-3, determined the role of thymine protein-coding frames of RNA sequences (Bio information. 2008. 2, 304-307). In these results Human coronavirus (CoV-19/India -1st, 2nd & 3rd waves COVID-19 types 1-3 protein-coding RNA of Spike, Nucleocapsid, and RdRp play an important role in such a way to establishing host-pathogen interaction.

Severe acute respiratory syndrome-coronavirus-2 isolate Wuhan-Hu-1 SPIKE & Nucleocapsid-Frame-2 and RdRP-Frame-1: 1st COVID-19 wave 2020: 29903 bp +ssRNA

Human coronavirus hCoV-19/India/TG-RFCH00152_CIB1129/2020:SPIKE & Nucleocapsid-Frame-3 and RdRp-Frame-2: 1st COVID-19 wave 2020: 29814 bp RNA

Human coronavirus hCoV-19/India/TG-RFCH00254_CIB0664/2021:SPIKE & Nucleocapsid-Frame-2 and RdRp-Frame-1: 2nd COVID-19 wave 2021: 29014 bp RNA

Human coronavirus hCoV-19/India/TG-RFCH00327_CIB0737/2021:SPIKE & Nucleocapsid-Frame-1 and RdRp-Frame-3: 3rd COVID-19 wave 2021: 29784 bp RNA

5. Proposed Solution-PAN corona vaccine and PAN corona viral drug
Recombinant unique variant-specific PAN corona vaccine and RNA-Targeted small PAN corona viral drug discovery and development
Project Description:

This project aims to the development of Pan corona virus-specific RNA-dependent RNA polymerase (RdRp) using recombinant peptide. The genes coding for virus RNA dependent RNA polymerase (vrpRdRp) of Pan coronavirus (COVID-19) would be produced recombinantly in CHO cells, purified, and production in the Pan corona vaccine. The Pan coronavirus RNA dependent RNA polymerase (vrpRdRp) would Pan corona vaccines and Pan corona therapeutics.

Approach:

Aim: Targeting RNA-dependent RNA polymerase (RdRp) GeneX to set up an RNA-dependent RNA polymerase (vrpRdRp) would Pan corona vaccines and Pan corona therapeutics strategy.

Methods:

Our computational studies provide new insight into the various types of unique specific coronavirus Alpha, Beta, Gamma, Delta, lamda & Omicron i) Retrieving all coronavirus protein IDs (protein-coding ssRNA of Spike, Nucleocapsid, RdRp, NSP7-RdRp, NSP8-RdRp, NSP12-RdRp, etc.,) from NCBI. ii) Checking the protein expression of all coronavirus proteins across various types of coronavirus at the NCBI Virus sequences for the discovery database. iii) Calculating and visualization the protein expression correlation of top PAN coronavirus protein candidates across various types of PAN coronavirus using our in-house software analysis tools. iv) Coronavirus disease and disease-specific GeneX candidate identification: e.g.( i)Thirty in one Unique variant-specific peptide ii)fifteen in one Unique variant-specific peptide and iii)Twenty-Five-in-One Unique variant-specific peptide v) Development of GeneX viral-based Recombinant unique variant-specific peptide PAN corona Vaccine and RNA-Targeted small unique PAN coron a viral drug discovery and development therapeutic candidates demonstrating potential efficacy against for PAN COVID. vi) Cloning of genes encoding for RNA-dependent RNA polymerase (vrpRdRp) with proteins into CHO expression vector. vii) Optimization of protein expression and purification of proteins. viii) Optimization of RNA-dependent RNA polymerase (vrpRdRp) protein activity. ix) Development of novel RNA dependent RNA polymerase (vrpRdRp) based Pan corona vaccines and Pan corona therapeutics on e.g. GeneX.x) Application of novel RNA dependent RNA polymerase (vrpRdRp) Pan corona vaccines and Pan corona therapeutics in specific animal models models. xi) Proof of vrpRdRp concept in Pan corona vaccines and Pan corona therapeutics-specific animal models to be ready for clinical trials/patent application.

5.1Specific Goals PAN corona vaccine (PANCOVAC) and PAN corona viral drug (PANCOVIR)
i)Thirty-in-One, ii)Fifteen-in-One, and iii)Twenty-Five-in-One GeneX viral-based Recombinant unique variant-specific PAN corona vaccine candidates demonstrating potential efficacy against PANCOVID
a)5.1.1 LBPLPANCOVAC1-3

I) LBPLPANCOVAC-1 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based Recombinant Unique variant-specific PAN corona vaccine for PAN-COVID.

II) LBPLPANCOVAC-2 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based Recombinant unique variant-specific PAN corona vaccine for PAN-COVID.

III) LBPLPANCOVAC-3 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based Recombinant unique variant-specific PAN corona vaccine for PAN-COVID.i)Thirty-in-One, ii)Fifteen-in-One, and iii)Twenty-Five-in-One tri-specific GeneX PAN corona viral Drug candidates with strong binding targeting multiple microorganisms on the PANCOVID

b)5.1.2 LBPLPANCOVIR-1-3

I) LBPLPANCOVIR-1 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based RNA-Targeted small Unique PAN corona viral drug to treat severe cases of PAN-COVID.

II) LBPLPANCOVIR-2 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based RNA-Targeted small Unique PAN corona viral drug to treat severe cases of PAN-COVID.

III) LBPLPANCOVIR-3 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based RNA-Targeted small Unique PAN corona viral drug to treat severe cases of PAN-COVID. Read More About Products R&D Pipline

6.Consultancy / Contract Services

6.1The Lysine biotech has a consultancy processing stable cell line development for protein production of Biosimilar (mAbs, enzymes, etc.,) new drugs and Vaccine discovery to effectively transfer technologies on commercial basis as per the SAC committee recommendations. In addition the lysine biotech provides contract services to provide affordable, safe and effective New drugs, diagnosis, vaccine, enzymes and Biosimilar (mAbs, etc.,) for several applications in health care and industrial importance
6.2The Lysine biotech has a consultancy processing Chimeric antigen receptor (CAR)T-cells (Autologous & Allogeneic) development of mAb sequences used for CAR scFv are originated from Pangene Biotech Ltd effectively transfer technologies on commercial basis as per the SAC committee recommendations. In addition the lysine biotech provides contract services to provide affordable, safe and effective CAR T-cells for several applications in health care
Publications

I).Mayakrishnan Vijayakumar, BalakarthikeyanJanani, PriyaKannappan, Senthil Renganathan*, SameerAl-Ghamdi, Mohammed Alsaidan, Mohamed AAbdelaziz, Abubucker Peer Mohideen, Mohammad Shahid, Thiyagarajan Ramesh, 2021.In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies Saudi Journal of Biological Sciences. Oct.29-2021. doi: 10.1016/j.sjbs.2021.10.060.

II).Renganathan Senthil*, Manokaran Sakthivel, Singaravelu Usha, 2021. Structure-based drug design of peroxisome proliferator-activated receptor gamma inhibitors: ferulic acid and derivatives. J Biomol Struct Dyn. 39(4):1295-1311.doi: 10.1080/07391102.2020.1740790.

III).Konda Mani Saravanan, Haiping Zhang, Renganathan Senthil*, Kevin Kumar Vijayakumar, Vignesh Sounderrajan, Yanjie Wei, Harshavardhan Shakila, 2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. J Biomol Struct Dyn. 1-9.doi: 10.1080/07391102.2020.1834457.

IV).Mahendrarajan Venkatramanan, Pitchaipillai Sankar Ganesh, Renganathan Senthil*, Jeyachandran Akshay, Arumugam Veera Ravi, Kulanthaivel Langeswaran, Jamuna Vadivelu, Samuthira Nagarajan, Kaliaperumal Rajendran, Esaki Muthu Shankar, 2020. Inhibition of Quorum Sensing and Biofilm Formation in Chromobacterium violaceum by Fruit Extracts of Passiflora edulis. ACS Omega.5(40):25605-25616.doi: 10.1021/acsomega.0c02483.

V).Subrata Pramanik, Manisha Thaker, Ananda Gopu Perumal*, Rajasekaran Ekambaram, Naresh Poondla, Markus Schmidt, Pok‐Son Kim, Arne Kutzner, Klaus Heese, 2020. Proteomic Atomics Reveals a Distinctive Uracil‐5‐Methyltransferase. Molecular Informatics. Vol. 39, Issue 5,doi:10.1002/minf.201900135 .

Lysine Biotech